Two patients diagnosed with coexisting hematologic and oncologic BRAF V600E mutated malignancies. Which entity is really carrying the BRAF (V600E) mutation?
Schlick, K; Troch, M; Placher-Sorko, G; Faber, V; Neureiter, D; Greil, R; Hopfinger, G ONKOLOGIE. 2013; 36: 168-169.
The transcription factor IRF-4 is related to prognosis in Chronic Lymphocytic Leukemia (CLL) and involved in proliferation and survival
Asslaber, D; Hofbauer, JP; Zaborsky, N; Kocher, T; Hartmann, TN; Greil, R; Egle, A ONKOLOGIE. 2013; 36: 222-223.
CXCR3 modulates CXCL12-mediated cellular responses in chronic lymphocytic leukemia
Ganghammer, S; Hinterseer, E; Johrer, K; Greil, R; Hartmann, TN CYTOKINE. 2013; 63(3): 264-264.
Allogeneic stem cell transplantation in patients with acute myeloid leukaemia: a report from the Austrian Stem Cell Transplantation Registry (ASCTR)
Boehm, A; Rabitsch, W; Greinix, HT; Kalhs, P; Mitterbauer, M; Schulenburg, A; Woehrer, S; Worel, N; Strunk, D; Linkesch, W; Urban, C; Schwinger, W; Peters, C; Gastl, G; Nachbaur, D; Kircher, B; Clausen, J; Auberger, J; Krieger, O; Kasparu, H; Hauser, H; Machherndl-Spandl, S; Weltermann, A; Lindner, B BONE MARROW TRANSPL. 2013; 48: S393-S393.
Influence of Body Mass Index on survival in indolent and Mantle-cell Lymphomas: Analysis of the StiL1 trial
Weiss, L; Melchardt, T; Egle, A; Hopfinger, G; Greil, R; Barth, J; Rummel, M ONKOLOGIE. 2013; 36: 31-32.
MESENCHYMAL STEM CELLS RETAIN THEIR PRO-OLIGODENDROGENIC ACTIVITY DURING AGING: A RATIONALE FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE SCLEROSIS
Rivera, FJ; Wodnar, R; Feichtner, M; Oberbauer, E; Brachtl, G; Greil, R; Rohde, E; Franklin, RJM; Aigner, L GLIA. 2013; 61: S52-S52.
Tiam1/Rac1 signals contribute to CLL cell proliferation and chemoresistance
Hofbauer, SW; Krenn, PW; Ganghammer, S; Asslaber, D; Pichler, U; Wallner, M; Henschler, R; Greil, R; Hartmann, TN ONKOLOGIE. 2013; 36: 56-56.
Blockade of the Potassium Channel KCa3.1 inhibits proliferation in Chronic Lymphocytic Leukemia
Grossinger, EM; Weiss, L; Zierler, S; Hinterseer, E; Schmolzer, J; Asslaber, D; Hainzl, S; Egle, A; Pinon, JD; Hartmann, TN; Greil, R; Kerschbaum, HH ONKOLOGIE. 2013; 36: 191-192.
Updated report of the Austrian CML registry
Schmidt, S; Burgstaller, S; Linkesch, W; Greil, R; Schlogl, E; Fridrik, M; Krieger, O; Petzer, A; Lang, A; Mitterer, M; Valent, P; Walder, A; Sliwa, T; Keil, F; Korger, M; Hausler, C; Woll, E; Oexle, H; Schnallinger, M; Pober, M; Rochau, U; Siebert, U; Thaler, J; Gastl, G ONKOLOGIE. 2013; 36: 63-63.
Lapatinib plus Caelyx in patients with advanced or metastatic Her 2 positive breast cancer following failure of Trastuzumab therapy – A Phase II study of the Arbeitsgemeinschaft Medikamentose Tumortherapie
Pircher, M; Mlineritsch, B; Fridrik, M; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Ressler, S; Rinnerthaler, G; Ulmer, H; Greil, R ONKOLOGIE. 2013; 36: 159-159.